Float Short %

13.83

Margin Of Safety %

Put/Call OI Ratio

0.32

EPS Next Q Diff

0.04

EPS Last/This Y

-0.41

EPS This/Next Y

-0.62

Price

46.93

Target Price

60.78

Analyst Recom

Performance Q

-0.63

Relative Volume

0.82

Beta

2.22

Ticker: KYMR

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	KYMR	42.66	0.26	0.24	3440
2025-08-18	KYMR	43.61	0.28	0.38	1527
2025-08-19	KYMR	42.6	0.28	0.00	1593
2025-08-20	KYMR	42.35	0.28	0.02	1596
2025-08-21	KYMR	42.58	0.28	0.06	1617
2025-08-22	KYMR	44.09	0.27	2.00	1648
2025-08-25	KYMR	41.83	0.27	2.00	1648
2025-08-26	KYMR	43.87	0.27	0.00	1657
2025-08-27	KYMR	42.25	0.24	0.14	1843
2025-08-28	KYMR	41.76	0.24	0.00	1852
2025-08-29	KYMR	41.22	0.24	0.00	1857
2025-09-02	KYMR	40.69	0.24	5.33	1862
2025-09-03	KYMR	43.26	0.25	999.99	1879
2025-09-04	KYMR	42.21	0.25	0.00	1878
2025-09-05	KYMR	43.53	0.24	999.99	1920
2025-09-08	KYMR	43.26	0.32	999.99	2046
2025-09-09	KYMR	43.43	0.32	999.99	2051
2025-09-10	KYMR	43.48	0.32	0.67	2052
2025-09-11	KYMR	46.22	0.32	0.01	2055
2025-09-12	KYMR	47	0.32	0.33	2073
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	KYMR	42.62	-37.5	35.4	-3.41
2025-08-18	KYMR	43.64	-37.5	36.1	-3.41
2025-08-19	KYMR	42.57	0.4	49.8	-3.41
2025-08-20	KYMR	42.34	0.4	44.5	-3.41
2025-08-21	KYMR	42.58	0.4	41.4	-3.41
2025-08-22	KYMR	44.09	0.4	32.7	-3.40
2025-08-25	KYMR	41.83	-0.5	57.5	-3.42
2025-08-26	KYMR	43.87	-0.5	28.7	-3.42
2025-08-27	KYMR	42.28	-0.5	53.2	-3.42
2025-08-28	KYMR	41.75	-0.5	46.3	-3.42
2025-08-29	KYMR	41.21	-0.5	46.6	-3.42
2025-09-02	KYMR	40.68	-0.5	46.6	-3.39
2025-09-03	KYMR	43.24	-0.5	-66.1	-3.39
2025-09-04	KYMR	42.23	-0.5	-31.6	-3.39
2025-09-05	KYMR	43.51	-0.5	-53.5	-3.39
2025-09-08	KYMR	43.26	-0.5	-39.1	-3.39
2025-09-09	KYMR	43.44	-0.5	-42.9	-3.39
2025-09-10	KYMR	43.51	-0.5	-41.5	-3.39
2025-09-11	KYMR	46.20	-0.5	-65.6	-3.39
2025-09-12	KYMR	46.93	-0.5	-47.5	-3.39
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	KYMR	7.98	4.28	13.06
2025-08-18	KYMR	7.98	6.91	13.10
2025-08-19	KYMR	7.85	6.91	13.17
2025-08-20	KYMR	7.63	6.91	13.17
2025-08-21	KYMR	7.63	6.91	13.17
2025-08-22	KYMR	7.63	6.91	13.17
2025-08-25	KYMR	7.63	13.69	13.17
2025-08-26	KYMR	7.63	13.69	13.17
2025-08-27	KYMR	7.63	13.69	12.93
2025-08-28	KYMR	7.63	13.69	12.93
2025-08-29	KYMR	7.63	13.69	12.93
2025-09-02	KYMR	7.63	13.69	12.93
2025-09-03	KYMR	7.63	13.69	12.93
2025-09-04	KYMR	7.78	13.69	12.93
2025-09-05	KYMR	7.78	13.69	12.93
2025-09-08	KYMR	7.78	13.77	12.94
2025-09-09	KYMR	7.75	13.77	12.94
2025-09-10	KYMR	7.75	13.77	12.94
2025-09-11	KYMR	7.75	13.77	13.88
2025-09-12	KYMR	7.75	13.77	13.83
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.95

Avg. EPS Est. Current Quarter

-0.82

Avg. EPS Est. Next Quarter

-0.91

Insider Transactions

7.75

Institutional Transactions

13.77

Beta

2.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

48.9

Max Drawdown 5-Year %

-87.5

Target Price

60.78

P/E

Forward P/E

PEG

P/S

75.14

P/B

3.41

P/Free Cash Flow

EPS

-3.48

Average EPS Est. Cur. Y

-3.39

EPS Next Y. (Est.)

-4.01

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-616.03

Relative Volume

0.82

Return on Equity vs Sector %

-53.2

Return on Equity vs Industry %

-40.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.09

EBIT Estimation

-47.5

Kymera Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 218

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

stock quote shares KYMR – Kymera Therapeutics, Inc. Stock Price stock today

news today KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KYMR – Kymera Therapeutics, Inc. yahoo finance google finance

stock history KYMR – Kymera Therapeutics, Inc. invest stock market

stock prices KYMR premarket after hours

ticker KYMR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: KYMR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y